Charting your course through the Inflation Reduction Act storm
Published on February 16, 2024
The Medicare Drug Price Negotiation process as part of the US Inflation Reduction Act is underway, with the initial rounds of negotiations set to begin. We’re here to help you understand the challenges involved, and how to successfully navigate through them.
As we begin 2024, we are currently in the ‘calm before the storm’ when it comes to implementation of the Medicare Drug Price Negotiation process (as part of the Inflation Reduction Act).
The first cycle of negotiationManufacturers of the first ten drugs selected for negotiation [Table 1] have submitted their dossiers to CMS and presented their case on the appropriate comparator therapies and their value over those alternatives.
Table 1. List of 10 drugs selected for the Medicare Drug Price Negotiation Program (2026)Drug nameParticipating manufacturerEliquisBristol Myers Squibb JardianceBoehringer IngelheimXareltoJanssen PharmaJanuviaMerck Sharp DohmeFarxigaAstraZeneca AB …